白藜芦醇软胶囊对2型糖尿病患者血糖变异及胰岛素抵抗的影响

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (833 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨白藜芦醇软胶囊对2型糖尿病患者血糖变异及胰岛素抵抗的影响。方法采用随机数字表法将2型糖尿病80例分为A、B、C、D 4组:每组20例, A、B、C组在基础治疗上加白藜芦醇软胶囊。其中,A组: 250 mg/次,口服,2次/d;B组: 350 mg/次,口服,2次/d;C组:500 mg/次,口服,2次/d,治疗12周;D组为对照组(基础治疗);检测空腹血糖(FPG)、空腹胰岛素(FISN)糖化血红蛋白(HbA₁c)、血脂、胰岛素及三餐2h后血糖,计算MBG、血糖波动参数、胰岛素抵抗指数(HOMA-IR)和胰岛素敏感指数(ISI)。结果 C组和D组治疗前后各值均数差F各值均数差FPG:[(1.54±0.06) mmol/L vs (0.45±0.01) mmol/L,t=4.562, P=0.037)];FISN:[(4.85±0.35) pmol/ml vs (0.76±0.13)pmol/ml,t=3.467,P=0.025];HbA₁c:[(1.01±0.36)% vs(0.24±0.07)%,t=3.724,P=0.031];平均血糖值:[(1.91±0.22) )mmol/L vs (0.33±0.03) mmol/L,t=4.823, P=0.026]; 血糖变异性:[(1.22±0.23)mmol/L vs(0.07±0.03) mmol/L, t=4.025,P=0.027];血糖标准差:[(0.88±0.12)vs(0.02±0.01),t=3.681,P=0.032]较治疗前明显下降。C组治疗前后HOMA-IR由2级均降至1级、ISI的改善C组优于D组(P<0.01)。结论白藜芦醇软胶囊对血糖变异及胰岛素抵抗与剂量相关,一定剂量的白藜芦醇软胶囊可降低2型糖尿病患者的平均血糖波动度、血糖标准差,减少HOMA-IR,提高ISI;2型糖尿病患者在服用降糖药的同时,联合服用白藜芦醇软胶囊治疗是较好的选择。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张娴
	刘莉

关键词 ：白藜芦醇软胶囊, 2型糖尿病, 血糖变异, 胰岛素抵抗

Abstract：Objective To explore the effect of resveratrol soft capsules on glucose variability in patients with type 2 diabetes and on insulin resistance.Methods Using the random number table method, 80 patients with type 2 diabetes were equally divided into four groups.Group A, B and C were given resveratrol soft capsules for twelve weeks plus conventional treatment. Group A orally took resveratrol soft capsules 250 mg twice a day, Group B 350 mg, Group C 500 mg,while Group D served as the control group (conventional treatment).Fasting blood glucose, blood lipids, insulin and serum glucose 2h after meals were detected. MBG, serum glucose fluctuation parameters, the index of insulin resistance (HOMA IR) and insulin sensitive index (ISI)were calculated.Results FPG in Group C and Group D before and after treatment was[(1.54±0.06)mmol/L vs (0.45±0.01)mmol/L,t=4.562,P=0.037) ]respectively, FISN was[(4.85±0.35) pmol/ml vs (0.76±0.13)pmol/ml,t=3.467,P=0.025] respectively,and HbA₁c was[(1.01±0.36)% vs(0.24±0.07)%,t=3.724,P=0.031]respectively. The average serum glucose value was[(1.91±0.22)mmol/L vs (0.33±0.03) mmol/L,t=4.823,P=0.026]respectively,serum glucose variability was[(1.22±0.23)mmol/L vs (0.07±0.03)mmol/L,t=4.025,P=0.027]respectively, and serum glucose standard deviation was[(0.88±0.12) vs (0.02±0.01),t=3.681,P=0.032]. After treatment,HOMA IR in Group C was reduced from Grade Two to Grade One, and the ISI of Group C improved more significantly than that of Group D (P<0.01).Conclusions A particular dose of resveratrol soft capsules can reduce the average serum glucose, daytime serum glucose fluctuations,standard deviations of serum glucose and HOMA IR while improving ISI in patients with type 2 diabetes.Patients with type 2 diabetes should take resveratrol soft capsules in combination with other antidiabetic drugs.

Key words： resveratrol soft capsule type 2 diabetes glucose variability insulin resistance index

收稿日期: 2017-05-21

ZTFLH:

R587.1

基金资助:云南省昆明市西山区基金课题项目(西-2014012)

作者简介: 张娴,硕士研究生,主治医师。

引用本文:

张娴, 刘莉. 白藜芦醇软胶囊对2型糖尿病患者血糖变异及胰岛素抵抗的影响[J]. 武警医学, 2018, 29(1): 52-56. ZHANG Xian, LIU Li. Effect of resveratrol soft capsules on glucose variability in patients with type 2 diabetes and on insulin resistance. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(1): 52-56.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2018/V29/I1/52

[1]	董裕康,梁显泉,虞晓红.严重多发伤患者早期血糖变异度与预后的相关性研究[J].临床急诊杂志,2015,16(10):764-767.
[2]	Yki J H.Toxicity of hyperglycaemia in type 2 Diabetes[J].Diabetes/metabolism Reviews,1998,14 Suppl 1(S1):45-50.
[3]	Emerging R,Factors C,Sarwar N, et al .Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease:a collaborative meta-analysis of 102 prospective studies[J].Lancet,2010,375(9733):2215-2222.
[4]	罗丽君,徐成高,侍晓云,等.2型糖尿病伴血脂异常患者外周血白细胞及淋巴细胞的变化与临床意义[J].武警医学,2016,27(5):447-448.
[5]	张娴,刘莉,郭明,等.坎地沙坦与红景天联用的降压疗效及其对胰岛素抵抗的影响[J].武警医学,2014,25(3):261-263.
[6]	阿亮.血糖波动对重症患者预后影响的相关性研究[J].医学综述,2015,11(21):3975-3978.
[7]	魏琼,孙子林,金晖,等.血糖波动和糖尿病慢性并发症的分子机制研究进展[J].中华糖尿病杂志,2012, 4(9):560-563.
[8]	张星光,武晋晓,程千鹏,等.二甲双胍与艾塞那胎治疗新诊断2型糖尿病的疗效及其对血糖波动的影响[J].武警医学,2016,27(8):823-825.
[9]	彭璐,陈光,窦京涛,等.Klinefelter综合征患者糖代谢分析[J].中国糖尿病杂志,2017,9 (3):195-199.
[10]	高贝贝,郭雯,龚颖芸.2型糖尿病患者葡萄糖负荷后氨基酸水平变化及其与胰岛素抵抗的关系[J].中国糖尿病杂志,2016,25(1):19-24.
[11]	蔡耘,李晓芳,王楚涵,等.血糖变异性与危重症脑梗死患者预后的相关性[J].中国综合临床,2015,31(10):914-916.
[12]	张娴,刘莉.白藜芦醇软胶囊对糖尿病患者血糖及早期视网膜病变的疗效分析[J].武警医学,2016,27(8):806-809.
[13]	陈银,魏军平.白藜芦醇治疗糖尿病肾病的研究进展[J].医学综述,2015,10(19):3545-3547.
[14]	杨伟,华琦.衰老相关的慢性炎症与胰岛素抵抗的研究进展[J].中华糖尿病杂志,2017,1(16):68-70.